Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies

Clinical Cancer Research

Volumn 12, Issue 15, 2006, Pages 4499-4505

  Saldanha, Gerald ^a,c   Potter, Linda ^a   DaForno, Philip ^b   Pringle, J Howard ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; EXON; FEMALE; GENE MUTATION; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT LENTIGO; MELANOMA; MUTATION RATE; ONCOGENE N RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE STRAND CONFORMATION POLYMORPHISM; SKIN TUMOR; TUMOR CLASSIFICATION;

ADULT; AGED; AGED, 80 AND OVER; EXONS; FEMALE; GENE FREQUENCY; GENES, RAS; HUMANS; MALE; MELANOMA; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS;

EID: 33748053013     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2447     Document Type: Article

References (27)

1. Barnhill RL. Pathology of melanocytic nevi and malignant melanoma. Boston: Butterworth-Heinemann; 1995.
2. Bastian BC, Kashani-Sabet M, Hamm H, et al. Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. Cancer Res 2000;60:1968-73.
3. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
4. Maldonado JL, Fridlyand J, Patel H, et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 2003;95:1878-90.
5. Sasaki Y, Niu C, Makino R, et al. BRAF point mutations in primary melanoma show different prevalences by subtype. J Invest Dermatol 2004;123:177-83.
6. Davison JM, Rosenbaum E, Barrett TL, et al. Absence of V599E BRAF mutations in desmoplastic melanomas. Cancer 2005;103:788-92.
7. Edmunds SC, Cree IA, Di Nicolantonio F, Hungerford JL, Hurren JS, Kelsell DP. Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas. Br J Cancer 2003;88:1403-5.
8. Rimoldi D, Salvi S, Lienard D, et al. Lack of BRAF mutations in uveal melanoma. Cancer Res 2003;63:5712-5.
9. Cohen Y, Rosenbaum E, Begum S, et al. Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites. Clin Cancer Res 2004;10:3444-7.
10. Edwards RH, Ward MR, Wu H, et al. Absence of BRAF mutations in UV-protected mucosal melanomas. J Med Genet 2004;41:270-2.
11. Wong CW, Fan YS, Chan TL, et al. BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs. J Clin Pathol 2005;58:640-4.
12. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135-47
13. Takata M, Goto Y, Ichii N, et al. Constitutive activation of the mitogen-activated protein kinase signaling pathway in acral melanomas. J Invest Dermatol 2005;125:318-22.
14. Crowson AN, Magro CM, Mihm MC. Malignant melanoma. In: The melanocytic proliferations. A comprehensive textbook of pigmented lesions. New York: Wiley-Liss; 2001. p. 283.
15. Saldanha G, Purnell D, Fletcher A, Potter L, Gillies A, Pringle JH. High BRAF mutation frequency does not characterize all melanocytic tumor types. Int J Cancer 2004;111:705-10.
16. Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 2000;351:289-305.
17. Besaratinia A, Pfeifer GP. Biological consequences of 8-methoxypsoralen-photoinduced lesions: sequence-specificity of mutations and preponderance of T to C and T to A mutations. J Invest Dermatol 2004;123:1140-6.
18. Dhawan P, Singh AB, Ellis DL, Richmond A. Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-κB and tumor progression. Cancer Res 2002;62:7335-42.
19. Stahl JM, Sharma A, Cheung M, et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 2004;64:7002-10.
20. Chudnovsky Y, Adams AE, Robbins PB, Lin Q, Khavari PA. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations. Nat Genet 2005;37:745-9.
21. Skender-Kalnenas TM, English DR, Heenan PJ. Benign melanocytic lesions: risk markers or precursors of cutaneous melanoma? J Am Acad Dermatol 1995;33:1000-7.
22. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003;33:19-20.
23. Lee DA, Cohen JA, Twaddell WS, et al. Are all melanomas the same? Spitzoid melanoma is a distinct subtype of melanoma. Cancer 2006;106:907-13.
24. Miller CJ, Cheung M, Sharma A, et al. Method of mutation analysis may contribute to discrepancies in reports of (V599E)BRAF mutation frequencies in melanocytic neoplasms. J Invest Dermatol 2004;123:990-2.
25. Lang J, Mackie RM. Prevalence of exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral, and lentigo maligna subtypes. J Invest Dermatol 2005;125:575-9.
26. Bastian BC, Curtin J, Fridlyand J, et al. Braf and melanocytic diseases. Pigment Cell Res 2004;17:428.
27. Sawyers C. Targeted cancer therapy. Nature 2004;432:294-7.